AbbVie Inc. (NYSE:ABBV) Is Favoured by Institutional Owners Who Hold 73% of the Company
Investors in AbbVie (NYSE:ABBV) Have Seen Solid Returns of 262% Over the Past Five Years
AbbVie Options Trading: A Deep Dive Into Market Sentiment
Piper Ups Neurocrine to Overweight, Says '568 Still in the Game
AbbVie Inc. (ABBV) Is Attracting Investor Attention: Here Is What You Should Know
New Medicare Drug Price Caps Could Help Seniors Save Over $1,000 a Year - AARP
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Express News | Abbvie : Leerink Partners Raises Target Price to $206 From $196
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
SkinMedica Revolutionizes Skin Hydration With the Introduction of HA5 Hydra Collagen Replenish + Restore Hydrator
Study Results From Phase 1 Studies With Exidavnemab Published in The Journal of Clinical Pharmacology
Unusual Options Activity: ABBV, KHC and Others Attract Market Bets, ABBV V/OI Ratio Reaches 42.3
AbbVie Unusual Options Activity For August 26
Evercore ISI Raises Price Target on AbbVie to $192 From $180, Keeps Outperform Rating
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
Should You Be Excited About AbbVie Inc.'s (NYSE:ABBV) 78% Return On Equity?
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
AbbVie Analyst Ratings
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $209